Every Form 4 that Solid Biosciences Inc. (SLDB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SLDB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLDB filings page.
Solid Biosciences Inc. director Ian F. Smith increased his equity stake through equity compensation vesting. On July 2, 2026, he exercised restricted stock units to acquire 3,440 shares of Common Stock at a price of $0.00 per share, reflecting a conversion of vested awards rather than an open-market purchase.
The filing shows his direct holdings rose to 138,145 shares of Common Stock after the transaction, and he also holds 6,880 Restricted Stock Units. Footnotes state that restricted stock units convert to common stock on a one-for-one basis and were granted on January 2, 2026, vesting in equal quarterly installments over 12 months.
Solid Biosciences Inc. reported that director Nagendran Sukumar received a grant of stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and expire on June 10, 2036.
The grant vests in full on the earlier of the one-year anniversary of June 10, 2026 or immediately before the company’s next annual stockholder meeting after that date. Any remaining unvested portion will also vest automatically upon specified change in control events, aligning the director’s compensation with company performance and potential strategic transactions.
Solid Biosciences director Ian F. Smith received a grant of stock options covering 77,500 shares of common stock. The Director Stock Option has an exercise price of $6.61 per share and, after this grant, Smith holds options on 77,500 shares directly.
The option was granted on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders after the grant date. Any remaining unvested portion will also vest automatically upon specified change in control events. The option expires on June 10, 2036.
Solid Biosciences Inc. director Ilan Ganot received a new stock option grant. The Form 4 reports an award of 77,500 Director Stock Options, each exercisable for one share of common stock at an exercise price of $6.61 per share.
The option was granted on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholders’ meeting after the grant. Any remaining unvested portion will also vest automatically upon specified change in control events. Following this award, Ganot directly holds options for 77,500 underlying shares.
Solid Biosciences Inc. reported a Form 4 insider transaction showing a director stock option grant linked to board service. Options to purchase 77,500 shares of common stock at an exercise price of $6.61 per share were awarded to Board member Adam Stone as compensation.
The option vests in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the next annual stockholder meeting, with full acceleration upon specified change in control events. Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund Ltd. report an indirect pecuniary interest through a management fee offset and each disclaims beneficial ownership beyond that indirect interest.
Solid Biosciences Inc. director Georgia Keresty received a new stock option grant. On June 10, 2026, she was awarded options for 77,500 shares of common stock at an exercise price of $6.61 per share. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, and will also fully vest upon specified change in control events. Following this grant, her reported derivative holdings from this award total 77,500 options, expiring on June 10, 2036.
Solid Biosciences Inc. director Martin I. Freed received a grant of stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and were awarded at no upfront cost as a compensation grant.
The option vests in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the company’s next annual meeting of stockholders after that date, and will fully vest on specified change in control events. Following this grant, Freed holds 77,500 stock options directly.
Solid Biosciences Inc. director Clare Kahn received a grant of stock options to acquire 77,500 shares of common stock. The options have an exercise price of $6.61 per share and were awarded at no cost as equity compensation.
The option grant was made on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual stockholder meeting after the grant date. Any unvested portion will also vest automatically upon specified change in control events.
Solid Biosciences Inc. director Lynne Marie Sullivan received a grant of director stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and expire on June 10, 2036.
The grant was made on June 10, 2026 and vests in full on the earlier of the one-year anniversary of the grant date or immediately prior to the company’s next annual meeting of stockholders after the grant. Any unvested portion will vest automatically upon specified change in control events. This is a compensation-related award rather than an open-market purchase.
Solid Biosciences Inc. director Adam Leo Stone received a grant of stock options covering 77,500 shares of common stock. The options have an exercise price of $6.61 per share and were awarded at no cost as a compensation grant.
The option grant vests in full on the earlier of the one-year anniversary of the June 10, 2026 grant date or immediately before the company’s next annual stockholder meeting after that date. Any unvested portion will vest automatically upon specified change in control events, and the options expire on June 10, 2036.
Howton David T reported acquisition or exercise transactions in this Form 4 filing.
Solid Biosciences Inc. reported that Chief Operating Officer David T. Howton received a grant of 79,341 restricted stock units (RSUs), each representing a contingent right to one share of common stock. These RSUs relate to performance stock units granted on June 11, 2024, where 25% of the target RSUs vest upon each of four predetermined performance milestones.
The Board determined that the second performance milestone was met on January 29, 2026, triggering this portion of the award. The shares tied to this milestone are scheduled to vest in the first quarter of 2027, subject to Mr. Howton’s continued service with the company on the evaluation date. This is a compensation-related equity award, not an open-market stock purchase.
Brooks Gabriel reported acquisition or exercise transactions in this Form 4 filing.
Solid Biosciences Inc. Chief Medical Officer Brooks Gabriel reported an award of 58,847 restricted stock units (RSUs) tied to performance stock units. Each RSU represents a right to receive one share of common stock as it vests. These RSUs relate to the second of four performance milestones under PSUs originally granted on June 11, 2024.
The Board determined that the performance criteria for the second milestone were met on January 29, 2026. The associated RSUs will vest only if Gabriel continues to serve the company through the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
Solid Biosciences Inc. reported that President and CEO Alexander Cumbo acquired 169,401 restricted stock units (RSUs), each representing one share of common stock. These RSUs relate to performance stock units granted on June 11, 2024, which vest in four 25% performance tranches.
The Board determined that the performance criteria for the second Performance Milestone were met on January 29, 2026. Shares tied to this milestone will vest only if Cumbo continues serving with the company through the Evaluation Date, which is anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that Chief Technology Officer Paul Herzich acquired 54,925 restricted stock units (RSUs) linked to the company’s common stock as part of his equity compensation. These RSUs were earned under performance stock units (PSUs) originally granted on June 11, 2024.
The PSUs vest in four equal 25% tranches upon achieving independent, pre-set performance milestones tied to business objectives. The Board determined the second milestone was met on January 29, 2026, triggering this 54,925-unit award. These shares will actually vest only if Herzich remains in service on the related Evaluation Date, anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that CFO & Treasurer Kevin Tan acquired 56,647 restricted stock units tied to prior performance-based awards. Each unit represents a contingent right to receive one share of common stock, bringing his directly held RSU-based position reported in this filing to 56,647 units.
These RSUs relate to performance stock units granted on June 11, 2024, which vest in four equal 25% tranches upon achieving predetermined, non-market and non-financial performance milestones. The second milestone was certified as achieved on January 29, 2026, with the associated shares scheduled to vest only if he remains in service through an evaluation date anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that Chief Regulatory Officer Jessie Hanrahan acquired 54,925 restricted stock units (RSUs) as a compensation grant. Each RSU represents a contingent right to receive one share of Solid Biosciences common stock.
These RSUs relate to performance stock units (PSUs) granted on June 11, 2024. The PSUs vest in four 25% tranches upon achieving independent, Board‑determined performance milestones that are non‑market and non‑financial. The Board determined that the second performance milestone was met on January 29, 2026, and the related shares will vest subject to continued service through an evaluation date anticipated in the first quarter of 2027.
Solid Biosciences Inc. director Ian F. Smith exercised restricted stock units into common shares. On April 2, 2026 he converted 3,441 restricted stock units into 3,441 shares of common stock at a stated price of $0.00 per share.
The restricted stock units were granted on January 2, 2026 and vest in equal quarterly installments over 12 months from the grant date. Following this transaction, Smith holds 134,705 shares of common stock directly and 10,320 restricted stock units.
Solid Biosciences Inc. reported that entities associated with Perceptive Advisors received a grant of pre-funded warrants to acquire 8,912,655 shares of Common Stock. These pre-funded warrants carry a de minimis exercise price of $0.001 per share and were acquired at $5.609 per warrant.
The warrants are directly held by Perceptive Life Sciences Master Fund Ltd., with Perceptive Advisors LLC serving as its investment manager and Joseph Edelman as managing member of the Advisor. The warrants do not expire and are subject to a 9.99% Beneficial Ownership Limitation on exercise. The reporting persons disclaim beneficial ownership beyond any indirect pecuniary interest.
Solid Biosciences Inc. President and CEO Alexander Cumbo reported a combination of RSU vesting and a related tax sale. On February 13, 2026, he acquired 30,031 shares of common stock at $0.00 per share through the conversion of restricted stock units, increasing his directly held common stock.
On February 18, 2026, he sold 16,644 shares of common stock in an open‑market transaction at a weighted average price of $5.8233 per share to cover withholding taxes following the RSU vesting, under a pre‑existing automatic sales instruction that is not a discretionary trade. After these transactions, he directly owned 235,405 shares of common stock and 60,063 RSUs that vest over four years from the February 13, 2024 grant date.
Solid Biosciences Inc. Chief Regulatory Officer Jessie Hanrahan reported insider equity activity involving restricted stock units and related tax sales. On February 13, 2026, she acquired 8,125 shares of common stock through the exercise of restricted stock units at a price of $0.00 per share. On February 18, 2026, she sold 4,134 shares of common stock at a weighted average price of $5.8233 per share, with actual sale prices ranging from $5.23 to $6.14, to cover withholding taxes following RSU vesting under a pre-established automatic sell-to-cover instruction. After these transactions, she held 74,318 shares of common stock and 16,250 restricted stock units.
Solid Biosciences Inc. director Ilan Ganot reported a small net sale of shares mainly tied to restricted stock unit vesting and tax withholding.
An entity associated with his wife sold 2,658 shares of common stock in an open-market transaction at a weighted average price of $5.8233 per share, with individual trades ranging from $5.23 to $6.14. According to the disclosure, this sale was made to cover withholding taxes after previously granted restricted stock units vested and followed a durable automatic sales instruction adopted by Ms. Ganot, so it was not a discretionary trade.
On the same date, 4,861 restricted stock units held by Ms. Ganot converted into an equal number of common shares at no exercise price, reflecting the one-for-one RSU-to-share ratio. After these transactions, Mr. Ganot’s reported holdings include shares held individually, jointly with his spouse, and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences Inc. Chief Technology Officer Paul Herzich reported both an RSU vesting and a related stock sale. On February 13, 2026, he acquired 7,187 shares of common stock upon the exercise of 7,187 restricted stock units at $0.00 per share, increasing his direct common stock holdings to 76,254 shares.
On February 18, 2026, Herzich then sold 3,616 common shares in an open-market transaction at a weighted average price of $5.8233 per share, with actual prices ranging from $5.23 to $6.14. The company states this sale was solely to cover tax withholding following RSU vesting, under a pre-established automatic sales instruction, and does not represent a discretionary trade by Herzich. After the sale, he directly held 72,638 common shares.
Solid Biosciences Chief Operating Officer David T. Howton reported routine equity activity involving restricted stock units and related share sales. On February 13, 2026, RSUs granted on February 13, 2024 vested, resulting in the acquisition of 14,687 shares of common stock through a derivative conversion at a price of $0.00 per share. A corresponding RSU position of 14,687 units was reduced, leaving 29,376 RSUs outstanding. On February 18, 2026, 7,469 common shares were sold in the open market at a weighted average price of $5.8233 per share to cover withholding taxes following this vesting, under a durable automatic sales instruction adopted on August 16, 2024, so the sale was not a discretionary trade. After these transactions, Howton held 105,077 shares of common stock directly.
Solid Biosciences Inc. reported insider equity activity by Chief Medical Officer Gabriel Brooks. Previously granted restricted stock units (RSUs) vested, and each RSU converts into one share of common stock. On the vesting date, 10,937 RSUs were exercised into the same number of common shares at no cash exercise price.
A related sale of common stock was executed solely to cover withholding taxes under a pre‑established durable automatic sales instruction adopted on August 15, 2024. The company notes this sell‑to‑cover transaction was not a discretionary trade by Dr. Brooks. Following these transactions, Brooks directly held 89,466 common shares and 21,876 RSUs.
Solid Biosciences Inc. Chief Financial Officer and Treasurer Kevin Tan reported RSU vesting and related share activity. On February 13, 2026, 10,625 restricted stock units converted into 10,625 shares of common stock at no cost, leaving 21,250 RSUs outstanding and 104,826 common shares held directly.
On February 18, 2026, Tan sold 5,404 common shares at a weighted average price of $5.8233 per share to cover withholding taxes after the RSU vesting, under a durable automatic sales instruction adopted on August 15, 2024. The sale was not a discretionary trade, and he now directly holds 99,422 common shares.
Solid Biosciences Chief Operating Officer sells shares to cover taxes. On February 4, 2026, COO David T. Howton sold 18,894 shares of Solid Biosciences common stock at a weighted average price of $6.4419 per share.
The filing explains this was an automatic sale to cover withholding taxes after restricted stock units vested, under a pre-established durable automatic sale instruction. It states the transaction was not a discretionary trade. After this sale, Howton directly owned 97,859 shares of common stock.
Solid Biosciences Inc. President and CEO Alexander Cumbo reported an automatic sale of common stock tied to tax withholding. On February 4, 2026, he sold 48,913 shares of Solid Biosciences common stock at a weighted average price of $6.4419 per share.
The filing explains this was a sell-to-cover transaction to satisfy withholding taxes after previously granted restricted stock units vested, executed under a durable automatic sale instruction letter adopted on August 18, 2024. After this activity, Cumbo directly beneficially owned 222,018 common shares.
Solid Biosciences Inc. director Ilan Ganot reported an indirect sale of 7,205 shares of common stock on February 4, 2026 at a weighted average price of $6.4419 per share. The shares were held through his spouse and sold to cover withholding taxes after previously granted restricted stock units vested, under a durable automatic sell-to-cover instruction, so the transaction was not a discretionary trade.
Following this transaction, Ganot is reported as beneficially owning 25,271 shares indirectly through his wife, 99,297 shares directly (including shares held individually and jointly with Annie Ganot), and 19,394 shares indirectly through the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences Inc. CFO and Treasurer Kevin Tan reported an automatic sale of 14,783 shares of common stock on February 4, 2026. The shares were sold at a weighted average price of $6.4419 per share, in multiple trades between $6.28 and $6.60.
The sale was made solely to cover withholding taxes after previously granted restricted stock units vested, under a durable automatic sale instruction letter adopted on August 15, 2024, and is not a discretionary trade by Mr. Tan. Following this transaction, he directly holds 94,201 common shares.
Solid Biosciences Inc. Chief Medical Officer Gabriel Brooks reported an automatic sale of 12,616 shares of common stock on February 4, 2026. The shares were sold at a weighted average price of $6.4419 per share to cover withholding taxes upon vesting of previously granted restricted stock units, under a durable automatic sale instruction letter.
After this tax-withholding sale, Dr. Brooks beneficially owns 84,092 shares of Solid Biosciences common stock in direct form. The company’s disclosure notes that the transaction did not represent a discretionary trade by Dr. Brooks, and that the individual sale prices ranged from $6.28 to $6.60 per share.
Solid Biosciences Inc. insider transaction: Chief Regulatory Officer Jessie Hanrahan reported an automatic sale of common stock tied to tax withholding. On February 4, 2026, 12,348 shares of common stock were sold at a weighted average price of $6.4419 per share to cover withholding taxes after restricted stock units vested. The filing notes this was executed under a pre-established durable automatic sale instruction and is not a discretionary trade. After the transaction, Hanrahan beneficially owned 70,327 shares of Solid Biosciences common stock in direct ownership.
Solid Biosciences Inc. Chief Technology Officer Paul Herzich reported a small, routine share sale on a Form 4. On February 4, 2026, he sold 10,905 shares of common stock at a weighted average price of $6.4419 per share.
According to the filing, the sale was made solely to cover withholding taxes after previously granted restricted stock units vested, under a pre-established durable automatic sale instruction. It was not a discretionary trade. After this transaction, Herzich beneficially owned 69,067 shares directly.
Solid Biosciences CFO & Treasurer Kevin Tan reported multiple equity transactions. On January 29, 2026, 56,646 performance stock units converted one-for-one into common stock, increasing his directly held common shares to 102,746. That same day he received an employee stock option for 187,000 shares vesting over four years and a new grant of 93,500 restricted stock units, also vesting over four years.
On January 31, 2026, 33,075 restricted stock units from a prior 2025 grant vested and converted into common stock, lifting his direct holdings to 135,821 shares. On February 2, 2026, he sold 26,837 shares at a weighted average price of $6.4369 solely to cover withholding taxes under a pre-arranged automatic sell-to-cover instruction, leaving 108,984 common shares held directly.
Solid Biosciences Inc.’s President and CEO Alexander Cumbo reported multiple equity compensation events and a tax-related share sale. On January 29, 2026, 169,401 performance stock units vested into common shares, he received an option grant for 509,850 shares at $6.60, and was granted 254,900 RSUs.
On January 31, 2026, 100,400 RSUs from a prior grant vested into common stock. On February 2, 2026, Cumbo sold 80,258 shares at a weighted average price of $6.4369 to cover withholding taxes under an automatic sell-to-cover instruction, leaving him with 270,931 directly held common shares plus unvested RSUs and options.
Solid Biosciences Inc. Chief Regulatory Officer Jessie Hanrahan reported equity vesting, new grants, and a tax-related share sale. On January 29, 2026, 54,925 performance stock units converted into common stock and 190,000 employee stock options plus 95,000 restricted stock units were granted.
On January 31, 2026, 27,625 restricted stock units vested into common shares. On February 2, 2026, 26,535 common shares were sold at a weighted average price of $6.4369 to cover withholding taxes under a pre-established automatic sell-to-cover instruction, leaving 82,675 common shares held directly.
Solid Biosciences Inc. Chief Medical Officer Gabriel Brooks reported multiple equity compensation events and a related stock sale. On January 29, 2026, 58,847 performance stock units vested into common stock after a performance milestone was certified as achieved, increasing his holdings before later transactions.
That same day, he received an option to buy 207,450 shares at an exercise price of $6.60 per share, vesting over four years, and 103,750 restricted stock units that also vest over four years in 25% annual installments. On January 31, 2026, 28,225 restricted stock units from a 2025 grant vested into common stock.
On February 2, 2026, Brooks sold 28,335 shares of common stock at a weighted average price of $6.4369 per share to cover withholding taxes after PSU vesting under a pre-arranged automatic sell-to-cover instruction. Following these transactions, he directly held 96,708 shares of Solid Biosciences common stock.
Solid Biosciences’ Chief Operating Officer David Howton reported multiple equity compensation events and a related share sale. On January 29, 2026, 79,341 performance stock units vested and converted into common stock, and he received 105,100 new restricted stock units plus an option for 210,200 shares at an exercise price of $6.60 per share, all vesting over four years.
On January 31, 2026, an additional 42,275 restricted stock units vested and converted into common stock. On February 2, 2026, he sold 37,771 shares of common stock at a weighted average price of $6.4369 solely to cover withholding taxes under a pre-established automatic sell-to-cover instruction, and continued to hold 116,753 shares directly afterward.
Solid Biosciences Chief Technology Officer Paul Herzich reported several equity award events and a related share sale. On January 29, 2026, 54,925 performance stock units vested and converted one-for-one into common stock after a performance milestone was certified as achieved.
On the same date, he received an option to buy 170,000 shares at an exercise price of $6.60 per share, vesting over four years, and was granted 85,000 restricted stock units, also vesting over four years. On January 31, 2026, 24,675 RSUs from a 2025 grant vested and converted into common shares.
On February 2, 2026, Herzich sold 26,250 common shares at a weighted average price of $6.4369 per share to cover withholding taxes after PSU vesting, under a durable automatic sell-to-cover instruction, and not as a discretionary trade. After these transactions, he directly owned 79,972 common shares.
Solid Biosciences director Ilan Ganot reported several equity compensation events and updated holdings. On January 29, 2026, an entity associated with his wife received an employee stock option for 70,900 shares of common stock at an exercise price of $6.6 per share, vesting over four years. On the same date, his wife was also granted 35,450 restricted stock units (RSUs), which vest in four equal annual installments.
On January 31, 2026, 15,000 RSUs associated with his wife were settled into 15,000 shares of common stock, increasing her indirect common stock holdings to 32,476 shares and RSU holdings to 45,000 units. Separately, Ganot directly and jointly holds 99,297 shares of common stock and an additional 19,394 shares are held in the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences Inc. director Ilan Ganot reported routine equity compensation activity and a small tax-related share sale. On January 27, 2026, previously granted restricted stock units converted one-for-one into common stock, including 389 shares for his wife and 3,884 shares for him.
On January 28, 2026, 191 common shares indirectly held through his wife were sold at $6.59 per share to cover withholding taxes under a pre-established automatic sell-to-cover instruction and were not a discretionary trade. Following these events, he beneficially owns 95,255 shares individually, 4,042 shares jointly with Annie Ganot, 17,476 shares indirectly through his wife, and 19,394 shares through the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences Inc. CFO & Treasurer Kevin Tan reported routine equity transactions. On January 9, 2026, 11,250 restricted stock units (RSUs) converted into the same number of common shares at an exercise price of $0.00, reflecting scheduled vesting. On January 13, 2026, he sold 5,704 shares of common stock at $5.27 per share.
According to the disclosure, this sale was made solely to cover withholding taxes under an automatic “sell-to-cover” instruction adopted on August 15, 2024, and is described as not a discretionary trade by Mr. Tan. After these transactions, he directly holds 46,100 shares of common stock and 11,250 RSUs, with RSUs converting to common stock on a one-for-one basis and vesting in four equal annual installments from January 9, 2023.
Solid Biosciences director Ian F. Smith reported multiple equity award transactions. On 01/02/2026, he received a stock option for 18,012 shares of common stock at an exercise price of $5.45 per share and a grant of 13,761 restricted stock units (RSUs). These “Smith Equity Awards” vest in equal quarterly installments over 12 months from the grant date, with full acceleration if the Smith Agreement ends early or there is a change in control of the company.
On 01/06/2026, 4,573 previously granted RSUs fully vested and converted to 4,573 shares of common stock on a one‑for‑one basis. After these transactions, Smith directly held 131,264 shares of Solid Biosciences common stock, along with 18,012 options and 13,761 RSUs.
Solid Biosciences Inc. director Ilan Ganot reported equity transactions related to spouse-held awards and updated his share holdings. On January 3, 2026, 2,994 restricted stock units held by his wife converted into 2,994 shares of common stock, reflecting one-for-one conversion of these awards. On January 5, 2026, 1,053 shares of common stock associated with his wife were sold at $5.43 per share to cover withholding taxes after the vesting of previously granted restricted stock units, and the filing notes these sales do not represent a discretionary trade by Ms. Ganot.
Following these transactions, 17,278 shares of common stock are reported as indirectly owned through his wife. The filing also reports 95,413 shares of common stock held directly by Mr. Ganot (including shares held jointly with Annie Ganot) and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust, for which Adam and Annie Ganot serve as trustees.
Solid Biosciences (SLDB) director Ilan Ganot reported an open-market sale of common stock. On 11/10/2025, he sold 3,278 shares at a weighted average price of $4.12, executed in multiple trades within a $4.11–$4.12 range.
Following the transaction, he beneficially owned 95,412 shares directly. Additional indirect holdings reported include 14,839 shares held by his spouse and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences (SLDB) Form 4: Chief Medical Officer Gabriel Brooks reported RSU vesting and a related tax sale. On 10/18/2025, 9,750 restricted stock units converted to common stock on a one-for-one basis. On 10/20/2025, 2,895 shares were sold at $5.96 to cover withholding taxes under a previously adopted durable automatic sale instruction letter, characterized as a sell-to-cover and not a discretionary trade.
Following these transactions, Brooks beneficially owned 33,819 common shares, held directly. The filing notes an additional 19,500 RSUs beneficially owned after the reported transactions. The RSU grant from 10/18/2023 vests over four years at 25% on each anniversary of the grant date.